<DOC>
	<DOC>NCT01892345</DOC>
	<brief_summary>The primary objective of the study is to assess the efficacy and safety of eculizumab treatment as compared to placebo in relapsing NMO patients using a time to first relapse study design.</brief_summary>
	<brief_title>A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study)</brief_title>
	<detailed_description />
	<mesh_term>Neuromyelitis Optica</mesh_term>
	<criteria>Key 1. Male or female patients ≥ 18 years old 2. Diagnosis of NMO or NMO spectrum disorder 3. All patients must be NMOIgG seropositive 4. Clinical evidence of at least 2 relapses in last 12 months or 3 relapses in the last 24 months (with at least 1 relapse in the 12 months prior to the Screening) 5. EDSS score ≤7 6. Immunosuppressive therapy is allowed provided patients have been on a stable maintenance dose prior to the Screening and remain on a stable dose for the duration of the study Key 1. Use of rituximab within 3 months prior to screening 2. Use of mitoxantrone within 3 months prior to screening 3. Use of IVIg within 3 weeks prior to screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Neuromyelitis Optica</keyword>
	<keyword>Neuromyelitis Optica Spectrum Disorder</keyword>
	<keyword>Devic's disease, Transverse Myelitis</keyword>
	<keyword>Optic Neuritis</keyword>
	<keyword>relapse</keyword>
	<keyword>eculizumab</keyword>
	<keyword>soliris</keyword>
	<keyword>NMO-IgG</keyword>
	<keyword>CNS Autoimmune Disorders</keyword>
	<keyword>Demyelinating Disorders</keyword>
</DOC>